US Patent 9,050,308: Claim Scope, Expiration, Litigation Risk, and Omega-3 Patent Landscape

US Patent 9,050,308 protects a method of treating severe hypertriglyceridemia with a 2- to 4-gram daily oral dose of an omega-3 composition containing specified ranges of EPA, DHA, and DPA, with at least 90% of the polyunsaturated fatty acids in free-acid form. The patent is directed to an Epanova-type omega-3 carboxylic acid composition rather than to purified EPA products such as Vascepa or generic icosapent ethyl.

The principal infringement risk arises when a product combines all of the following elements: a mixed EPA/DHA/DPA composition, the claimed concentration ranges, predominantly free-fatty-acid chemistry, a 2- or 4-gram daily dose, and treatment of patients with triglycerides of at least 500 mg/dL.

What does US Patent 9,050,308 claim?

The patent claims a treatment method, not a composition standing alone. Independent claim 1 requires each of these limitations:

Claim element	Requirement
Disease state	Severe hypertriglyceridemia
Patient population	Pretreatment serum or plasma triglycerides of at least 500 mg/dL
Administration route	Oral
Dose	2 to 4 grams per day
EPA content	50% to 60% by weight
DHA content	17% to 23% by weight
DPA content	1% to 8% by weight
Chemical form	At least 90% by weight of the polyunsaturated fatty acid is in free-acid form
Treatment result	Triglycerides fall below pretreatment levels
Duration	Long enough to produce the reduction

The claim uses “comprising.” That term generally leaves the claim open to additional ingredients, excipients, fatty acids, antioxidants, flavoring agents, and other formulation components, provided the accused product still satisfies the recited limitations.

The patent issued June 9, 2015, as US 9,050,308 B2. The patent is associated with the omega-3 carboxylic acid development program originally conducted by Omthera Pharmaceuticals and later acquired by AstraZeneca. The claimed composition corresponds closely to the Epanova development profile. (U.S. Patent No. 9,050,308, 2015; AstraZeneca, 2013.)

How do the dependent claims narrow the patent scope?

Claims 2 through 11 create narrower versions of claim 1.

Claim	Narrowing limitation
2	At least 95% of polyunsaturated fatty acid is in free-acid form
3	DPA is at least 1.5%
4	DPA is at least 2%
5	DPA is at least 2.5%
6	DPA is at least 3%
7	DPA is at least 3.5%
8	DPA is at least 4%
9	DPA is at least 4.5%
10	Dose is 2 grams per day
11	Dose is 4 grams per day

Claims 3 through 9 form a concentration ladder. Each claim inherits the limitations of claim 1 and adds a minimum DPA concentration. Because claim 1 already permits DPA from 1% to 8%, the dependent claims cover progressively narrower subranges.

Claim 9 depends from claim 7 rather than directly from claim 1. It therefore requires at least 4.5% DPA, while also retaining the other limitations inherited through claim 7.

Claims 10 and 11 are commercially important because they isolate the two most likely commercial dosing regimens. A product administered at 2 grams daily may implicate claim 10. A product administered at 4 grams daily may implicate claim 11.

What products fall within the literal scope of US 9,050,308?

A product is a strong literal match when its active lipid profile is approximately:

EPA: 50% to 60%;
DHA: 17% to 23%;
DPA: 1% to 8%;
at least 90% free fatty acids;
administered orally at 2 or 4 grams per day;
used in patients with triglycerides of at least 500 mg/dL.

A typical Epanova-type product would be closer to the claim than Lovaza or Vascepa because Epanova was developed as a mixture of omega-3 free fatty acids, including EPA, DHA, and DPA.

Epanova

Epanova was an investigational omega-3 carboxylic acid product developed for severe hypertriglyceridemia. Its composition and free-fatty-acid presentation align with the technical limitations in US 9,050,308.

Epanova was not approved by the FDA as a marketed prescription product. AstraZeneca discontinued development after the STRENGTH cardiovascular outcomes trial failed to show a cardiovascular benefit in the studied population. Because no approved Epanova product created an FDA Orange Book reference product, the patent did not generate the same conventional Paragraph IV pathway associated with approved drugs. (ClinicalTrials.gov, 2020; Nicholls et al., 2020.)

Vascepa and generic icosapent ethyl

Vascepa contains icosapent ethyl, an ethyl ester of EPA. It does not ordinarily satisfy the requirement that at least 90% by weight of the polyunsaturated fatty acid be present in free-acid form. It also lacks the claimed DHA and DPA profile.

Vascepa is therefore outside the most direct literal scope of claim 1. Its patent estate has centered on purified EPA, cardiovascular risk reduction, and methods of use rather than on an EPA/DHA/DPA free-acid mixture. (FDA, 2019; Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 2020.)

Lovaza and generic omega-3-acid ethyl esters

Lovaza and generic omega-3-acid ethyl ester products contain EPA and DHA primarily as ethyl esters. That chemistry differs from the claimed free-acid form. Their standard compositions also do not appear designed to satisfy the claimed DPA range.

These products present a weaker literal infringement risk under US 9,050,308, although product-specific analytical testing would be necessary. The claim is not defeated merely because a product contains EPA and DHA. The free-acid percentage and DPA limitations are central.

What formulations are protected by US Patent 9,050,308?

The patent protects a treatment using a composition with a defined fatty-acid profile. It does not require a particular capsule shell, tablet, excipient, flavor system, particle size, or manufacturing process.

The formulation categories most exposed are:

Omega-3 free-fatty-acid mixtures.
EPA/DHA products that naturally contain measurable DPA.
Products with approximately 50% to 60% EPA and 17% to 23% DHA.
Products dosed at 2 or 4 grams daily.
Products labeled or promoted for triglycerides of at least 500 mg/dL.

The claim does not require that EPA, DHA, or DPA be chemically isolated. A naturally derived mixture can satisfy the claim if the measured composition falls within the specified ranges.

The use of “weight percent” creates an analytical issue. The relevant denominator must be determined from the patent specification, prosecution history, product testing methodology, and claim construction. A manufacturer cannot reliably assess freedom to operate from a certificate of analysis that reports only total oil composition if the patent’s percentage calculations are based on total polyunsaturated fatty acid content.

How strong is the patent estate for US 9,050,308?

The patent is technically narrow but commercially relevant for a specific product profile.

Strengths

It targets a clinically defined patient population.
It recites a commercially plausible dose of 2 or 4 grams daily.
The EPA and DHA ranges are broad enough to capture a defined omega-3 mixture.
The free-acid requirement distinguishes the invention from older ethyl-ester products.
The dependent claims create fallback positions based on DPA concentration and free-acid purity.
Method claims can be asserted against conduct involving labeled treatment of qualifying patients.

Weaknesses

Every limitation must be satisfied.
The composition must contain all three specified fatty acids within the claimed ranges.
The free-acid limitation creates a substantial design-around route.
The patient must have pretreatment triglycerides of at least 500 mg/dL.
The method requires a reduction below pretreatment triglyceride levels.
A product used only for a different indication may avoid direct literal infringement, although labeling and promoted use remain relevant.
The claims do not broadly cover purified EPA, ethyl esters, phospholipid formulations, or compositions outside the stated ranges.

The result is a focused patent rather than a platform patent covering all prescription omega-3 therapies.

When does US Patent 9,050,308 lose exclusivity?

The patent issued in 2015 and is subject to the standard US patent term measured from the applicable earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any corrections recorded in the USPTO file.

The relevant nominal term is generally expected to run to approximately 2029 or 2030 based on the patent family’s priority and filing chronology. The precise expiration date must be taken from the USPTO Patent Center record and the issued patent’s term-adjustment data. A patent issue date alone does not establish the expiration date.

Because Epanova was not approved, this patent did not receive the practical commercial benefit of FDA regulatory exclusivity or an Orange Book-linked generic waiting period.

What is the Orange Book status of US 9,050,308?

US 9,050,308 is not an Orange Book patent for Epanova because Epanova did not receive FDA approval as a marketed reference product.

This distinction matters:

The patent can still be enforceable against infringing conduct.
It does not create an Orange Book-listed patent dispute for an unapproved product.
It does not automatically trigger a Hatch-Waxman Paragraph IV certification.
It does not provide regulatory exclusivity independent of an approved drug.
A future applicant seeking approval for a product with the claimed composition would generally face a different patent-certification analysis if the patent were listed for an approved reference product, but no such Epanova listing exists.

The Orange Book patents for Vascepa and other approved omega-3 products are separate from US 9,050,308 and should not be treated as evidence that this patent covers those products. (FDA, 2024.)

Which companies are challenging US 9,050,308?

There is no well-established Orange Book Paragraph IV challenge directed specifically to US 9,050,308 because the associated Epanova product was not approved and did not create a standard FDA reference-product pathway.

The major generic litigation in the omega-3 market has involved other products and patents, particularly Vascepa and icosapent ethyl. Hikma’s abbreviated new drug application litigation against Amarin concerned Vascepa patents and induced infringement issues, not the Epanova composition claimed in US 9,050,308. (Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 2020.)

A company developing an equivalent free-fatty-acid EPA/DHA/DPA product could instead face:

A declaratory judgment action;
A direct patent infringement action;
A product-launch injunction request;
A section 271(b) induced-infringement theory based on labeling;
A validity challenge involving written description, enablement, anticipation, or obviousness.

What patent litigation affects the omega-3 market?

The principal litigated omega-3 patent dispute was Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. The Federal Circuit affirmed liability for induced infringement based on Hikma’s product labeling and the foreseeable use of generic icosapent ethyl for the patented indication.

That decision has limited direct application to US 9,050,308 because the patented technology differs. Its practical relevance is that an ANDA label, promotional materials, dosing instructions, and foreseeable prescribing patterns can influence induced-infringement analysis. A generic manufacturer cannot assume that omission of an indication eliminates risk if the remaining label encourages use covered by a method claim.

How does US 9,050,308 compare with competing omega-3 patent estates?

Product or estate	Main active form	DHA/DPA mixture required?	Free-acid requirement	Main patent exposure
US 9,050,308 / Epanova-type	Omega-3 free fatty acids	Yes	At least 90%	Severe hypertriglyceridemia method
Vascepa	Icosapent ethyl	No	No	Purified EPA and cardiovascular methods
Lovaza	EPA/DHA ethyl esters	No claimed DPA profile	No	Ethyl-ester omega-3 products
Generic omega-3-acid ethyl esters	EPA/DHA ethyl esters	No	No	Product-specific generic and formulation patents
Prescription fish-oil mixtures	Variable	Often variable	Usually not	Composition, purity, and use claims

US 9,050,308 is narrower than the broad commercial category of prescription omega-3 products. Its closest competitors are free-fatty-acid mixtures with EPA, DHA, and DPA, not purified EPA or ethyl-ester products.

What generic launch risks exist?

A generic or follow-on product faces the highest risk when it reproduces the patented profile and label:

2 or 4 grams daily;
treatment of triglycerides of at least 500 mg/dL;
EPA at 50% to 60%;
DHA at 17% to 23%;
DPA at 1% to 8%;
at least 90% free fatty acids.

Potential design-around strategies include:

converting the fatty acids into ethyl esters or another ester form;
reducing EPA below 50%;
reducing DHA below 17% or increasing it above 23%;
reducing DPA below 1%;
changing the product to purified EPA;
using a dose outside the claimed 2- to 4-gram range;
avoiding labeling for severe hypertriglyceridemia.

Design-around success depends on the final product composition, the proposed label, actual prescribing behavior, and any doctrine-of-equivalents analysis. Changing one formulation variable may avoid literal infringement but does not eliminate litigation risk if the overall product is substantially equivalent to the claimed method.

Does US 9,050,308 cover biologics or biosimilars?

No. The patent concerns small-molecule and naturally derived lipid constituents. Biosimilar provisions under the Biologics Price Competition and Innovation Act are not relevant.

The applicable competitive pathway is a conventional drug framework involving an NDA, ANDA, 505(b)(2) application, or commercial product outside the FDA approval pathway. Any patent dispute would turn on product composition, labeling, use, and method-of-use conduct rather than biosimilar interchangeability.

What licensing deals affect the patent?

Omthera Pharmaceuticals was acquired by AstraZeneca in 2013. That transaction transferred control of Omthera’s Epanova program and associated intellectual property to AstraZeneca. Epanova development was later discontinued after the STRENGTH trial failed its primary cardiovascular endpoint.

The acquisition is commercially relevant because ownership and enforcement rights may have moved through the Omthera-AstraZeneca corporate structure. A current freedom-to-operate review should rely on the USPTO assignment record rather than historical press releases alone. (AstraZeneca, 2013; ClinicalTrials.gov, 2020.)

Key Takeaways

US 9,050,308 is a method-of-treatment patent for severe hypertriglyceridemia.
The claim requires an EPA/DHA/DPA mixture, not purified EPA alone.
The composition must contain 50% to 60% EPA, 17% to 23% DHA, and 1% to 8% DPA.
At least 90% of the polyunsaturated fatty acid must be in free-acid form.
The claimed doses are 2 to 4 grams daily, with dependent claims specifically covering 2 grams and 4 grams.
Epanova is the closest commercial analogue.
Vascepa and Lovaza are materially different because they use purified EPA or ethyl-ester chemistry.
Epanova was not FDA approved, so US 9,050,308 did not create an Orange Book-linked Paragraph IV pathway.
The nominal patent term likely reaches approximately 2029 or 2030, subject to the official USPTO term calculation.
The principal design-around routes involve changing chemical form, fatty-acid percentages, dose, or labeled patient population.

FAQs

Can a product with EPA and DHA infringe US 9,050,308 without containing DPA?

Generally, no. DPA is an express limitation of claim 1. A product with no DPA, or DPA below the claimed minimum, has a strong argument against literal infringement, subject to the specific analytical record and any doctrine-of-equivalents theory.

Does the patent cover a 1-gram daily dose?

No. Claims 1 through 11 require a dose of 2 to 4 grams per day. A 1-gram regimen is outside the literal dose range.

Does the patent cover triglycerides below 500 mg/dL?

Claim 1 requires pretreatment serum or plasma triglycerides of at least 500 mg/dL. Treatment of patients below that threshold is outside the literal scope of the independent claim.

Can a manufacturer avoid the patent by using triglyceride or ethyl-ester forms?

Changing from free fatty acids to an ester form is a substantial design-around because the claim requires at least 90% of the polyunsaturated fatty acid to be in free-acid form. The final formulation and analytical method remain controlling.

Is US 9,050,308 relevant to a biosimilar application?

No. It concerns a nonbiologic omega-3 drug composition. A conventional drug approval and patent analysis, rather than a biosimilar interchangeability analysis, is applicable.

References

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 927 F.3d 1148 (Fed. Cir. 2020).

AstraZeneca. (2013). AstraZeneca to acquire Omthera Pharmaceuticals and its novel dyslipidemia product Epanova. AstraZeneca press release.

ClinicalTrials.gov. (2020). STRENGTH: Outcomes study to assess STatin Residual risk reduction with Epanova in hiGh cardiovascular risk patienTs with hypertriglyceridemia. National Library of Medicine.

U.S. Food and Drug Administration. (2019). VASCEPA (icosapent ethyl) prescribing information. FDA.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

U.S. Patent No. 9,050,308. (2015). Methods of treating severe hypertriglyceridemia. United States Patent and Trademark Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	9,050,308	⤷ Start Trial				TREATMENT OF HYPERTRIGLYCERIDEMIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013201793	⤷ Start Trial
Brazil	112014016788	⤷ Start Trial
Canada	2860512	⤷ Start Trial
Chile	2014001803	⤷ Start Trial
China	104321055	⤷ Start Trial
China	107050457	⤷ Start Trial
China	108524483	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,050,308

Which drugs does patent 9,050,308 protect, and when does it expire?

Summary for Patent: 9,050,308